ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kyowa Kirin Co.,Ltd.
  3. Financials
  4. Capital expenditures

Kyowa Kirin Co.,Ltd. (4151)

Market cap
¥1.26T
P/E ratio
16.7x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCapital expenditures (Million JPY)YoY (%)
Dec 31, 2025-37,715+44.85%
Dec 31, 2024-26,037+51.26%
Dec 31, 2023-17,213+10.59%
Dec 31, 2022-15,564+138.64%
Dec 31, 2021-6,522-35.52%
Dec 31, 2020-10,115+43.88%
Dec 31, 2019-7,030+66.15%
Dec 31, 2018-4,231-79.54%
Dec 31, 2016-20,675+8.48%
Dec 31, 2015-19,058-37.45%
Dec 31, 2014-30,466

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat